LISTEN NOW: Get the Skinny on GLP-1s: Part 2 — Pharmacy Friends podcast

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use.

February 12, 2024

The use of glucagon-like peptide-1 agonist (GLP-1s) as a tool for chronic weight management is one of the hottest topics in the health care industry, but if you take a closer look at the real-world data, the story becomes much more complex.

In this second of a two-part episode of the Pharmacy Friends podcast, “The Skinny on GLP-1s: Part 2,” Maryam Tabatabai, vice president for clinical information, is joined by David Lassen, a clinic pharmacist and Chief Clinical Officer, and Pat Gleason, assistant vice president of Health Outcomes. They will shine a light on Prime/MRx’s recent real-world study on GLP-1 drugs and their use for weight loss.

These three experts discuss how their data shows low adherence and increased costs in the first year and how they hope to see additional data to refine our guidance on GLP1s and chronic weight management approaches.

“We know for a fact that GLP-1s lower weight, and we know that they can be used in a way to do that very effectively,” Lassen said. “But I don’t think we assume that, because they’re very effective, that there’s total cost of care improvements.”

Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming, and most importantly, what it means to you. You can listen to the full episode “The Skinny on GLP-1s: Part 2,” on primetherapeutics.com/pharmacy-friends.

Related news

Perspectives

June 14, 2024

High-Cost Therapy Profile: June 2024

Detailed information about Imetelstat Intravenous (IV)

Perspectives

June 14, 2024

July 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market

Perspectives

May 30, 2024

Drug Approvals Monthly Update: May 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…